Clinical Trial Update: A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics and safety study evaluating the effect of repeat dosing of trametinib on a combined oral contraceptive in female subjects with cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Norethindrone/Ethinyl Estradiol (norethindrone + ethinyl estradiol)
• Trametinib (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: WITHDRAWN